Through strength, weaponry, and character, Autobots in the Transformers franchise, like Optimus Prime and Superion, are ...

Jazz Phar­ma­ceu­ti­cals will buy North Car­oli­na biotech Chimerix for $935 mil­lion in cash, the com­pa­nies said Wednes­day morn­ing.

STORY HIGHLIGHTS Jazz Pharmaceuticals to acquire Chimerix for $935 million to strengthen oncology portfolio. Chimerix's drug dordaviprone targets rare, aggressive brain tumors in children.

(Il Sole 24 Ore Radiocor) - Milano, 5 mar - The Ireland incorporated Jazz Pharmaceuticals said that ... representing a total consideration of approximately 935 million. The transaction is expected ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay ...

(JAZZ), Wednesday announced a deal to acquire Chimerix Inc. (CMRX) for $8.55 per share in cash, or a total consideration of around $935 million. Under the terms, Jazz will commence an all-cash ...

Jazz Pharmaceuticals has agreed to buy fellow biopharmaceutical company Chimerix for about $935 million in a deal that expands its oncology portfolio. Jazz on Wednesday said it will pay $8.55 a ...

Jazz Pharma to acquire Chimerix for $8.55 per share, totaling $935M, with closing expected in Q2 2025. FDA has set an Aug. 18, 2025, target date for Chimerix’s dordaviprone NDA for recurrent H3 ...

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will ...

Jazz Pharmaceuticals is expanding its foothold in cancer drug research, announcing Wednesday it will pay $935 million to buy Chimerix and an experimental medicine under Food and Drug ...